Roche licenses Rona's ALK7-targeting RNAi candidate for obesity and metabolic diseases

Roche has licensed Rona's ALK7-targeting RNAi candidate for obesity and metabolic diseases, with Rona eligible for up to $1.06 billion in milestones plus royalties.

Detected & updated continuously · Source: Nebula